Completed PHASE3 INTERVENTIONAL 1-arm NCT01472614

Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

Effect of Add-on Therapy With DLBS3233 on Glycemic Control, Lipid Profile, and Adiponectin in Patients With Type-2 Diabetes Mellitus

Sponsor: Dexa Medica Group

Conditions Type-2 Diabetes Mellitus

Interventions DLBS3233

Updated 5 times since 2017 Last updated: May 24, 2013 Started: Sep 30, 2011 Primary completion: Jan 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type-2 Diabetes Mellitus, this trial is completed. The trial is conducted by Dexa Medica Group and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dexa Medica Group

Data source: Dexa Medica Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Surabaya, Indonesia